Literature DB >> 23066343

Pharmaceutical approval update.

Marvin M Goldenberg.   

Abstract

Lorcaserin (Belviq), an appetite suppressant; pertuzumab (Perjeta) for HER-2- positive metastatic breast cancer; MenHibrix vaccine for meningococcal infections and influenza; icosapent ethyl (Vascepa) for reducing triglycerides; and aclidinium inhalation (Tudorza) powder for bronchospasm in COPD.

Entities:  

Year:  2012        PMID： 23066343      PMCID： PMC3462608     

Source DB:  PubMed          Journal:  P T        ISSN： 1052-1372


  2 in total

Review 1.  The evolution of biosimilars in oncology, with a focus on trastuzumab.

Authors:  N A Nixon; M B Hannouf; S Verma
Journal:  Curr Oncol       Date:  2018-06-13       Impact factor: 3.677

2.  Structural basis for molecular recognition at serotonin receptors.

Authors:  Chong Wang; Yi Jiang; Jinming Ma; Huixian Wu; Daniel Wacker; Vsevolod Katritch; Gye Won Han; Wei Liu; Xi-Ping Huang; Eyal Vardy; John D McCorvy; Xiang Gao; X Edward Zhou; Karsten Melcher; Chenghai Zhang; Fang Bai; Huaiyu Yang; Linlin Yang; Hualiang Jiang; Bryan L Roth; Vadim Cherezov; Raymond C Stevens; H Eric Xu
Journal:  Science       Date:  2013-03-21       Impact factor: 47.728
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.